TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care
At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.
Previous Post
New Federal Rules Affecting Coverage of Treatment for Gender Dysphoria: Considerations for States
Next Post
Reinstatement of Medical Experts
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago